Inhibition of S-phase kinase-associated protein 2-mediated p27 degradation suppresses tumorigenesis and the progression of hepatocellular carcinoma

Qi,Ming; Liu,Dongmei; Zhang,Shuhong; Hu,Peixin; Sang,Tan

doi:10.3892/mmr.2015.3156

Inhibition of S-phase kinase-associated protein 2-mediated p27 degradation suppresses tumorigenesis and the progression of hepatocellular carcinoma

Authors:
- Ming Qi
- Dongmei Liu
- Shuhong Zhang
- Peixin Hu
- Tan Sang
View Affiliations

Affiliations: Department of Digestive System, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China, Department of Transfusion Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China, Department of Hematology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
Published online on: January 8, 2015 https://doi.org/10.3892/mmr.2015.3156
Pages: 3934-3940

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to determine the protein expression of S‑phase kinase‑associated protein 2 (Skp2) and p27kip1, and to evaluate their possible prognostic values in malignant liver cancer, tissue samples from 50 patients and 40 controls were assessed and analyzed by immunohistochemistry and western blot analysis. Positive expression of Skp2 was observed in 35 (70.0%) of the hepatocellular carcinoma samples; however, the positive expression of p27kip1 was observed in 6 (15.0%) of the hepatocellular carcinoma samples. The expression of Skp2 was significantly negatively correlated with the expression of p27 (P<0.01). The results from Annexin V‑propidium iodide staining and MTT assays indicated that interference of Skp2 significantly induced apoptosis and inhibited the proliferation of SSMC‑7721 cells. In addition, the levels of endogenous p27 increased in the HepG2 and SSMC‑7721 cells following transfection with siRNA specific to Skp2, suggesting that the Skp2‑mediated degradation of p27kip1 was important in the proliferation of tumor cells. The present study, therefore, provided a molecular reference for the treatment of liver cancer.

View Figures

View References

1	Singh S, Fujii LL, Murad MH, et al: Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 11:1573–1584. 2013. View Article : Google Scholar : PubMed/NCBI
2	Tanaka K, Ichikawa Y and Endo I: Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol. 16:452–463. 2011. View Article : Google Scholar : PubMed/NCBI
3	Leenders MW, Nijkamp MW and Borel Rinkes IH: Mouse models in liver cancer research: a review of current literature. World J Gastroenterol. 14:6915–6923. 2008. View Article : Google Scholar : PubMed/NCBI
4	Coviello E, Caputi G, Martinelli D, Germinario CA and Prato R: Mortality trends for primary liver cancer in Puglia, Italy. Eur J Cancer Prev. 19:417–423. 2010. View Article : Google Scholar : PubMed/NCBI
5	Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138. 2013.PubMed/NCBI
6	Baillargeon J, Snyder N, Soloway RD, et al: Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep. 124:120–126. 2009.PubMed/NCBI
7	Chen JG and Zhang SW: Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 21:59–69. 2011. View Article : Google Scholar
8	Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 56:918–928. 1985. View Article : Google Scholar : PubMed/NCBI
9	Lobry C, Oh P, Mansour MR, Look AT and Aifantis I: Notch signaling: switching an oncogene to a tumor suppressor. Blood. 123:2451–2459. 2014. View Article : Google Scholar : PubMed/NCBI
10	Elliman SJ, Howley BV, Mehta DS, Fearnhead HO, Kemp DM and Barkley LR: Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers. Oncogenesis. 3:e1132014. View Article : Google Scholar : PubMed/NCBI
11	Liu Z, Fu Q, Lv J, Wang F and Ding K: Prognostic implication of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma: a tissue microarray study. J Exp Clin Cancer Res. 27:512008. View Article : Google Scholar : PubMed/NCBI
12	Newbold A, Salmon JM, Martin BP, Stanley K and Johnstone RW: The role of p21 and p27 in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma. Oncogene. Dec 2–2013.(Epub ahead of print). View Article : Google Scholar
13	Gao J, Zhao Y, Lv Y, et al: Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells. Cancer Cell Int. 13:22013. View Article : Google Scholar : PubMed/NCBI
14	Wei W, Ayad NG, Wan Y, et al: Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature. 428:194–198. 2004. View Article : Google Scholar : PubMed/NCBI
15	Bashir T, Dorrello NV, Amador V, Guardavaccaro D and Pagano M: Control of the SCF (Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature. 428:190–193. 2004. View Article : Google Scholar : PubMed/NCBI
16	Chen G, Wang Y, Garate M, Zhou J and Li G: The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system. Oncogene. 29:1498–1508. 2010. View Article : Google Scholar
17	Cheng H, Meng J, Wang G, et al: Skp2 regulates subcellular localization of PPARgamma by MEK signaling pathways in human breast cancer. Int J Mol Sci. 14:16554–16569. 2013. View Article : Google Scholar : PubMed/NCBI
18	Wang Z, Gao D, Fukushima H, et al: Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta. 1825:11–17. 2012.
19	Wei Z, Jiang X, Qiao H, et al: STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal. 25:931–938. 2013. View Article : Google Scholar : PubMed/NCBI
20	Pateras IS, Apostolopoulou K, Koutsami M, et al: Downregulation of the KIP family members p27 (KIP1) and p57 (KIP2) by SKP2 and the role of methylation in p57 (KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer. 119:2546–2556. 2006. View Article : Google Scholar : PubMed/NCBI
21	Saleem M, Maddodi N, Abu Zaid M, et al: Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res. 14:2119–2127. 2008. View Article : Google Scholar : PubMed/NCBI
22	Adhami VM, Siddiqui IA, Ahmad N, Gupta S and Mukhtar H: Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 64:8715–8722. 2004. View Article : Google Scholar : PubMed/NCBI
23	Nishitani H, Sugimoto N, Roukos V, et al: Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J. 25:1126–1136. 2006. View Article : Google Scholar : PubMed/NCBI
24	Peng L, Xu Z, Zhou Y, et al: Effect of rosiglitazone on cells cycle, apoptosis and expression of Skp2 and p27Kip1 in hepatocellular carcinoma cell line. Zhonghua Gan Zang Bing Za Zhi. 18:148–149. 2010.(In Chinese). PubMed/NCBI
25	Schulman BA, Carrano AC, Jeffrey PD, et al: Insights into SCF ubiquitin ligases from the structure of the Skp1–Skp2 complex. Nature. 408:381–386. 2000. View Article : Google Scholar : PubMed/NCBI
26	Li Y, Huang W, Huang S, Du J and Huang C: Screening of anti-cancer agent using zebrafish: comparison with the MTT assay. Biochem Biophys Res Commun. 422:85–90. 2012. View Article : Google Scholar : PubMed/NCBI
27	Sarzaeem A, Zare Mirakabadi A, Moradhaseli S, Morovvati H and Lotfi M: Cytotoxic effect of ICD-85 (venom-derived peptides) on HeLa cancer cell line and normal LK cells using MTT assay. Arch Iran Med. 15:696–701. 2012.PubMed/NCBI
28	Sylvester PW: Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol. 716:157–168. 2011. View Article : Google Scholar : PubMed/NCBI
29	Liu Y, Wang Y, Cheng C, et al: A relationship between p27 (kip1) and Skp2 after adult brain injury: implications for glial proliferation. J Neurotrauma. 27:361–371. 2010. View Article : Google Scholar
30	Rosner M and Hengstschläger M: Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem. 279:48707–48715. 2004. View Article : Google Scholar : PubMed/NCBI
31	Hu D, Liu W, Wu G and Wan Y: Nuclear translocation of Skp2 facilitates its destruction in response to TGFbeta signaling. Cell Cycle. 10:285–292. 2011. View Article : Google Scholar : PubMed/NCBI
32	Foster JS, Fernando RI, Ishida N, Nakayama KI and Wimalasena J: Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem. 278:41355–41366. 2003. View Article : Google Scholar : PubMed/NCBI
33	Pavlides SC, Huang KT, Reid DA, et al: Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer. Endocrinology. 154:4030–4045. 2013. View Article : Google Scholar : PubMed/NCBI
34	Kudo M: Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets. 12:1062–1072. 2012.PubMed/NCBI
35	Montalvo-Jave EE, Villegas-Alvarez F, Montalvo-Arenas CE, et al: Liver transplantation: some advances in liver cancer, live liver donation, and cell transplantation. A literature review. Rev Gastroenterol Mex. 74:341–348. 2009.
36	Shanmugasundaram K, Block K, Nayak BK, et al: PI3K regulation of the SKP-2/p27 axis through mTORC2. Oncogene. 32:2027–2036. 2013. View Article : Google Scholar :
37	Assoian RK and Yung Y: A reciprocal relationship between Rb and Skp2: implications for restriction point control, signal transduction to the cell cycle and cancer. Cell Cycle. 7:24–27. 2008. View Article : Google Scholar : PubMed/NCBI
38	Bashir T, Pagan JK, Busino L and Pagano M: Phosphorylation of Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase and its subcellular localization. Cell Cycle. 9:971–974. 2010. View Article : Google Scholar : PubMed/NCBI
39	Calvisi DF, Pinna F, Ladu S, et al: The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease. Int J Cancer. 126:1275–1281. 2010.
40	Wei Z, Jiang X, Liu F, et al: Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo. Tumour Biol. 34:181–192. 2013. View Article : Google Scholar
41	Wu J, Lee SW, Zhang X, et al: Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex. Oncogene. 32:78–85. 2013. View Article : Google Scholar :
42	Wu L, Grigoryan AV, Li Y, et al: Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol. 19:1515–1524. 2012. View Article : Google Scholar : PubMed/NCBI
43	Zheng XY, Ding W, Xie LP and Chen ZD: Correlation of Skp2 and P27kip1 protein expression and clinicopathological features of prostate cancer. Ai Zheng. 23:215–218. 2004.(In Chinese). PubMed/NCBI
44	Ben-Izhak O, Lahav-Baratz S, Meretyk S, et al: Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J Urol. 170:241–245. 2003. View Article : Google Scholar : PubMed/NCBI
45	Radke S, Pirkmaier A and Germain D: Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene. 24:3448–3458. 2005. View Article : Google Scholar : PubMed/NCBI